# Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US.

*fintech · news · 2026-05-06 · The Manila Times*

## Key points

- Novo Nordisk's Q1 2026 sales were boosted by a $4.2 billion 340B provision reversal in the US.
- Excluding the 340B reversal, adjusted US sales dropped 11% due to lower realised prices.
- Wegovy pill, launched January 2026 in the US, achieved over 2 million prescriptions by mid-April.
- FDA approved injectable Wegovy HD, delivering 20.7% mean weight loss in the STEP UP trial.
- FDA also approved Awiqli, the first-ever once-weekly basal insulin for type 2 diabetes.

**Companies:** Novo Nordisk
**Countries:** Denmark, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/06/tmt-newswire/globenewswire/novo-nordisks-adjusted-operating-profit-reached-dkk-32858-million-in-q1-2026/2336789)

---

Canonical: https://newsio.io/n/cd5a3f3b-69fd-4398-af02-66ddf4f41319/q1-2026-reported-sales-increased-by-32-at-cer-positively-impacted-by-a-provision
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works